Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other financing activities (2016 - 2025)

Coherus Oncology's Other financing activities history spans 11 years, with the latest figure at $22000.0 for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $22000.0; the TTM value through Dec 2025 reached -$832000.0, down 133.74%, while the annual FY2025 figure was -$832000.0, 2034.88% down from the prior year.
  • Other financing activities for Q4 2025 was $22000.0 at Coherus Oncology, up from -$1.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $4.6 million in Q4 2022 and bottomed at -$2.0 million in Q2 2021.
  • The 5-year median for Other financing activities is $305000.0 (2023), against an average of $881631.6.
  • The largest annual shift saw Other financing activities soared 2658.33% in 2022 before it plummeted 11440.0% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$180000.0 in 2021, then skyrocketed by 2658.33% to $4.6 million in 2022, then fell by 5.28% to $4.4 million in 2023, then tumbled by 99.77% to $10000.0 in 2024, then soared by 120.0% to $22000.0 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other financing activities are $22000.0 (Q4 2025), -$1.1 million (Q3 2025), and $16000.0 (Q2 2025).